Number of the records: 1
Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response
- 1.ADKINS, I., SADÍLKOVÁ, I., HRADILOVÁ, N., TOMALA, J., TOMALOVÁ, B., KOVÁŘ, M., MIKYSKOVÁ, R., REINIŠ, M., DE MARTYNOFF, G., BECHARD, D., MOEBIUS, U., SPÍŠEK, R. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Research. 2018, 78(13 S). ISSN 0008-5472. E-ISSN 1538-7445. Available: doi: 10.1158/1538-7445.AM2018-3775
Number of the records: 1